Royalty Pharma plc

NasdaqGS:RPRX 주식 보고서

시가총액: US$16.1b

Royalty Pharma 관리

관리 기준 확인 3/4

Royalty Pharma CEO는 Pablo Legorreta, Jan1996 에 임명되었습니다 의 임기는 28.83 년입니다. 는 $ 131.65M 가치에 해당하는 회사 주식의 0.82% 직접 소유합니다. 131.65M. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 4.4 년입니다.

주요 정보

Pablo Legorreta

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기28.8yrs
CEO 소유권0.8%
경영진 평균 재임 기간2.1yrs
이사회 평균 재임 기간4.4yrs

최근 관리 업데이트

Recent updates

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Oct 14
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Oct 09
Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Aug 28
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Jul 22
Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25
Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

CEO 보상 분석

Pablo Legorreta 의 보수는 Royalty Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

US$673m

Mar 31 2024n/an/a

US$799m

Dec 31 2023n/an/a

US$1b

Sep 30 2023n/an/a

US$184m

Jun 30 2023n/an/a

US$255m

Mar 31 2023n/an/a

US$332m

Dec 31 2022n/an/a

US$43m

Sep 30 2022n/an/a

US$507m

Jun 30 2022n/an/a

US$466m

Mar 31 2022n/an/a

US$602m

Dec 31 2021US$50mUS$8m

US$620m

Sep 30 2021n/an/a

US$783m

Jun 30 2021n/an/a

US$972m

Mar 31 2021n/an/a

US$493m

Dec 31 2020US$56mn/a

US$495m

Sep 30 2020n/an/a

US$2b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$29mn/a

US$2b

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Pablo 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Pablo 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Pablo Legorreta (60 yo)

28.8yrs

테뉴어

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...


리더십 팀

이름위치테뉴어보상소유권
Pablo Legorreta
Founder28.8yrs데이터 없음0.82%
$ 131.6m
Terrance Coyne
Executive VP & CFOno dataUS$4.56m0.19%
$ 30.2m
George Lloyd
Executive VP of Investments & Chief Legal Officer2.1yrsUS$4.56m0.24%
$ 38.6m
Christopher Hite
Vice Chairman & Executive VP4.6yrsUS$4.56m0.083%
$ 13.3m
Marshall Urist
Executive Vice President of Research & Investments3.9yrsUS$4.56m0.015%
$ 2.4m
Arthur McGivern
Executive Vice President of Investments & General Counsel2.1yrs데이터 없음데이터 없음
Ashwin Pai
Executive Vice President of Investments1.6yrs데이터 없음데이터 없음
Kristin Stafford
Senior VP & Chief Accounting Officerno data데이터 없음데이터 없음
Eric Schneider
Senior VP & Chief Technology Officer1.2yrs데이터 없음데이터 없음
James Reddoch
Executive VP of Investments & Chief Scientific Officer3.9yrsUS$3.40m데이터 없음
George Grofik
Senior VP and Head of Investor Relations & Communicationsno data데이터 없음데이터 없음
Molly Sawaya
Executive VP & Head of Human Capitalless than a year데이터 없음데이터 없음

2.1yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: RPRX 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Pablo Legorreta
Founder28.8yrs데이터 없음0.82%
$ 131.6m
David Hodgson
Independent Director2.4yrsUS$389.77k0.0037%
$ 588.6k
Ted Love
Independent Director4.3yrsUS$389.77k0.0082%
$ 1.3m
Errol De Souza
Independent Director4.4yrsUS$389.77k0.014%
$ 2.3m
Henry Fernandez
Lead Independent Director4.3yrsUS$389.77k0.023%
$ 3.7m
Gregory Norden
Independent Director4.4yrsUS$389.77k0.014%
$ 2.3m
Bonnie Bassler
Independent Director4.4yrsUS$389.77k0.011%
$ 1.8m
Catherine Engelbert
Independent Director4.4yrsUS$389.77k0.0076%
$ 1.2m

4.4yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: RPRX 의 이사회경험(평균 재직 기간 4.4 년)으로 간주됩니다.